Sargent Investment Group LLC Invests $225,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Sargent Investment Group LLC bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the fourth quarter, Holdings Channel.com reports. The firm bought 11,117 shares of the company’s stock, valued at approximately $225,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in TARS. SG Americas Securities LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 22.0% in the third quarter. SG Americas Securities LLC now owns 50,713 shares of the company’s stock worth $901,000 after acquiring an additional 9,141 shares during the last quarter. Raymond James & Associates bought a new position in shares of Tarsus Pharmaceuticals in the third quarter worth about $180,000. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 81.9% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 30,657 shares of the company’s stock worth $545,000 after acquiring an additional 13,801 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Tarsus Pharmaceuticals by 65.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after acquiring an additional 2,092 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Tarsus Pharmaceuticals in the third quarter worth about $198,000. Institutional investors own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TARS. Jefferies Financial Group raised their price objective on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Oppenheimer reiterated an “outperform” rating and issued a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. HC Wainwright raised their price objective on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Finally, Barclays raised their price objective on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $48.38.

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 4,436 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the sale, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, General Counsel Bryan Wahl sold 4,436 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the sale, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Aziz Mottiwala sold 4,766 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $145,839.60. Following the sale, the insider now directly owns 54,075 shares of the company’s stock, valued at approximately $1,654,695. The disclosure for this sale can be found here. Insiders sold a total of 24,496 shares of company stock valued at $749,578 in the last quarter. 11.54% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $32.04 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.93. Tarsus Pharmaceuticals, Inc. has a 52-week low of $12.57 and a 52-week high of $40.40. The firm has a 50 day moving average price of $34.02 and a two-hundred day moving average price of $24.97.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. During the same quarter in the previous year, the business posted ($0.49) EPS. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.25 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.